Genelux CORP Form 4 insider transactions

Genelux Corporation's Chief Technical Officer, Joseph Cappello, sold common stock on multiple dates to cover tax liabilities associated with restricted stock unit vesting.

Genelux Corporation's Head of Regulatory, Ralph Smalling, sold common stock on multiple dates in 2025 to cover tax liabilities related to restricted stock unit vesting.

Genelux Corporation Director Thomas John sold 10,000 shares of common stock for a weighted average price of $5.0008 per share on December 1, 2025, under a pre-arranged 10b5-1 trading plan.

GENELUX Corp's Head of Regulatory, Ralph Smalling, received 10,000 restricted stock units and had the exercise price of 8,333 stock options reduced to $3.33 per share.

Genelux Corporation's President and CEO, Thomas Zindrick, had over 1.3 million stock options repriced to an exercise price of $3.33 per share, effective September 1, 2025.

Genelux Corporation's SVP of Clinical Development, Yu Yong, saw the exercise prices of 272,652 stock options reduced to $3.33 per share, aligning with the common stock price on September 1, 2025.

Genelux Corporation's Chief Technical Officer, Joseph Cappello, had 175,000 stock options repriced to an exercise price of $3.33 per share, effective September 1, 2025.

Genelux Corporation director Mary Mirabelli was granted 22,283 restricted stock units and 28,576 stock options, increasing her beneficial ownership.

Genelux Corp. Director James L. Tyree acquired 22,283 restricted stock units and 28,576 stock options on August 27, 2025, increasing his beneficial ownership.

Genelux Director John Thomas acquired 22,283 restricted stock units and 28,576 stock options, increasing his beneficial ownership in the company.

Genelux Corporation's President and CEO, Thomas Zindrick, was granted 361,200 restricted stock units and options to purchase 478,800 shares of common stock.

Genelux Corporation's Head of Regulatory, Ralph Smalling, was granted 26,230 restricted stock units and options to purchase 34,770 shares of common stock.

Genelux Corporation's Director, John W. Smither, was granted 22,283 Restricted Stock Units and options to purchase 28,576 shares of common stock.

Genelux Corporation's SVP of Clinical Development, Yong Yu, received significant grants of restricted stock units and stock options, increasing beneficial ownership.

Genelux Corporation's Chief Technical Officer, Joseph Cappello, received significant equity grants including 107,500 restricted stock units and options to purchase 142,500 shares.

Genelux Corporation's General Counsel and Secretary, Eric Groen, was granted 270,000 stock options with an exercise price of $2.83, vesting over four years.

Genelux Corporation Director John Thomas reported the acquisition of 25,000 shares of common stock through a grant, increasing his direct beneficial ownership to 480,501 shares.

General Counsel Sean Ryder sold 4,475 shares of Genelux Corp stock on May 12, 2025, to cover estimated taxes related to vesting restricted stock units.

Genelux Corporation's CEO, Thomas Zindrick, sold 10,764 shares of common stock on May 12, 2025, to cover estimated taxes related to vesting restricted stock units.

Yu Yong, VP of Clinical Trial Operations at Genelux Corp, reports the sale of 5,579 shares of common stock at $2.92 per share to cover estimated taxes related to vesting restricted stock units.

Joseph Cappello, VP of Pharmaceutical Development at Genelux Corp, sold 4,737 shares of common stock to cover estimated taxes related to vesting restricted stock units.

Ralph Smalling, Head of Regulatory at Genelux Corp, sold 1,259 shares of common stock on May 12, 2025, to cover estimated taxes related to vesting restricted stock units.

Ralph Smalling, Head of Regulatory at Genelux Corp, reports acquisition of 4,172 shares of common stock upon vesting of restricted stock units on March 14, 2025.

Joseph Cappello, VP of Pharmaceutical Development at Genelux Corp, acquired 13,350 shares of common stock through the vesting of restricted stock units on March 14, 2025, and disposed of 57,003 shares.

VP of Clinical Trial Operations at Genelux Corp, Yu Yong, reports acquiring 13,350 shares of common stock on March 14, 2025, resulting in a total beneficial ownership of 53,219 shares.

General Counsel Sean Ryder reports acquisition of 10,708 shares and disposal of shares of Genelux Corp common stock on March 14, 2025.

Genelux Corp's CEO, Thomas Zindrick, reports acquiring 30,339 shares of common stock on March 14, 2025, and now beneficially owns 202,211 shares.

Genelux Corp's Chief Financial Officer, Matthew Pulisic, was granted 275,000 stock options with a strike price of $3.95, vesting over a period of 3.5 years.

A Genelux Corp director amended a previous filing to correct the exercise price of a stock option grant from $1.54 to $1.96 per share.

A Genelux Corp director filed an amended SEC Form 4 to correct the exercise price of a stock option grant.